Maurizio Taglialatela

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6320431/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Distinct epilepsy phenotypes and response to drugs in <i>KCNA1</i> gain―and lossâ€of function variants. Epilepsia, 2022, 63, .	5.1	20
2	Kv7.2 and Kv7.3 potassium channel subunits as new central regulators of blood pressure. Cardiovascular Research, 2022, 118, 345-346.	3.8	0
3	Kv7.4 channels regulate potassium permeability in neuronal mitochondria. Biochemical Pharmacology, 2022, 197, 114931.	4.4	8
4	Cerebrospinal Fluid Ion Analysis in Neonatal Seizures. Pediatric Neurology, 2022, 128, 16-19.	2.1	1
5	Gain of function due to increased opening probability by two <i>KCNQ5</i> pore variants causing developmental and epileptic encephalopathy. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2116887119.	7.1	14
6	The long and winding road to personalized medicine in KCNMA1â€linked channelopathies revealed by novel variants associated with the Liangâ€Wang syndrome. Acta Physiologica, 2022, 235, .	3.8	3
7	KCNQ2 R144 variants cause neurodevelopmental disability with language impairment and autistic features without neonatal seizures through a gain-of-function mechanism. EBioMedicine, 2022, 81, 104130.	6.1	19
8	Neurological risks and benefits of cytokineâ€based treatments in coronavirus disease 2019: from preclinical to clinical evidence. British Journal of Pharmacology, 2021, , .	5.4	2
9	KCNQ3 is the principal target of retigabine in CA1 and subicular excitatory neurons. Journal of Neurophysiology, 2021, 125, 1440-1449.	1.8	6
10	Generation of an iPSC line (UNINAi001-A) from a girl with neonatal-onset epilepsy and non-syndromic intellectual disability carrying the homozygous KCNQ3 p.PHE534ILEfs*15 variant and of an iPSC line (UNINAi002-A) from a non-carrier, unaffected brother. Stem Cell Research, 2021, 53, 102311.	0.7	4
11	"One Health―Approach for Health Innovation and Active Aging in Campania (Italy). Frontiers in Public Health, 2021, 9, 658959.	2.7	8
12	Synthesis and Pharmacological Characterization of Conformationally Restricted Retigabine Analogues as Novel Neuronal Kv7 Channel Activators. Journal of Medicinal Chemistry, 2020, 63, 163-185.	6.4	20
13	A Novel Kv7.3 Variant in the Voltage-Sensing S4 Segment in a Family With Benign Neonatal Epilepsy: Functional Characterization and in vitro Rescue by I²-Hydroxybutyrate. Frontiers in Physiology, 2020, 11, 1040.	2.8	7
14	Gabapentin treatment in a patient with KCNQ2 developmental epileptic encephalopathy. Pharmacological Research, 2020, 160, 105200.	7.1	7
15	The Role of Kv7.2 in Neurodevelopment: Insights and Gaps in Our Understanding. Frontiers in Physiology, 2020, 11, 570588.	2.8	35
16	A micro-bioimpedance meter for monitoring insulin bioavailability in personalized diabetes therapy. Scientific Reports, 2020, 10, 13656.	3.3	12
17	Calcium cytotoxicity sensitizes prostate cancer cells to standard-of-care treatments for locally advanced tumors. Cell Death and Disease, 2020, 11, 1039.	6.3	20
18	Epileptic channelopathies caused by neuronal Kv7 (KCNQ) channel dysfunction. Pflugers Archiv European Journal of Physiology, 2020, 472, 881-898.	2.8	62

#	Article	IF	CITATIONS
19	Neurobiology of coronaviruses: Potential relevance for COVID-19. Neurobiology of Disease, 2020, 143, 105007.	4.4	42
20	Genotype-phenotype correlations in patients with de novo <i>KCNQ2</i> pathogenic variants. Neurology: Genetics, 2020, 6, e528.	1.9	24
21	Management of epilepsy in elderly. Journal of Gerontology and Geriatrics, 2020, 68, 31-39.	0.5	0
22	Epileptic Encephalopathy In A Patient With A Novel Variant In The Kv7.2 S2 Transmembrane Segment: Clinical, Genetic, and Functional Features. International Journal of Molecular Sciences, 2019, 20, 3382.	4.1	17
23	Cardiac safety of secondâ€generation H ₁ â€antihistamines when updosed in chronic spontaneous urticaria. Clinical and Experimental Allergy, 2019, 49, 1615-1623.	2.9	33
24	Insights into the pathogenesis of ATP1A1 â€related CMT disease using patientâ€specific iPSCs. Journal of the Peripheral Nervous System, 2019, 24, 330-339.	3.1	4
25	A novel homozygous KCNQ3 lossâ€ofâ€function variant causes nonâ€syndromic intellectual disability and neonatalâ€onset pharmacodependent epilepsy. Epilepsia Open, 2019, 4, 464-475.	2.4	29
26	Activation of Kv7 Potassium Channels Inhibits Intracellular Ca2+ Increases Triggered By TRPV1-Mediated Pain-Inducing Stimuli in F11 Immortalized Sensory Neurons. International Journal of Molecular Sciences, 2019, 20, 4322.	4.1	8
27	Autism and developmental disability caused by <i>KCNQ3</i> gainâ€ofâ€function variants. Annals of Neurology, 2019, 86, 181-192.	5.3	73
28	Physical exercise for prevention of dementia (EPD) study: background, design and methods. BMC Public Health, 2019, 19, 659.	2.9	53
29	Genderâ€related issues in the pharmacology of new antiâ€obesity drugs. Obesity Reviews, 2019, 20, 375-384.	6.5	28
30	A novel mutation in <i>KCNQ3</i> â€related benign familial neonatal epilepsy: electroclinical features and neurodevelopmental outcome. Epileptic Disorders, 2019, 21, 87-91.	1.3	10
31	Kv7.3 Compound Heterozygous Variants in Early Onset Encephalopathy Reveal Additive Contribution of C-Terminal Residues to PIP2-Dependent K+ Channel Gating. Molecular Neurobiology, 2018, 55, 7009-7024.	4.0	21
32	Non-invasive real-time in-vivo monitoring of insulin absorption from subcutaneous tissues. Journal of Physics: Conference Series, 2018, 1065, 132008.	0.4	4
33	Identification of a Potent Tryptophan-Based TRPM8 Antagonist With in Vivo Analgesic Activity. Journal of Medicinal Chemistry, 2018, 61, 6140-6152.	6.4	31
34	Comparative Safety of Originator and Biosimilar Epoetin Alfa Drugs: An Observational Prospective Multicenter Study. BioDrugs, 2018, 32, 367-375.	4.6	9
35	De novo gainâ€ofâ€function variants in <i>KCNT2</i> as a novel cause of developmental and epileptic encephalopathy. Annals of Neurology, 2018, 83, 1198-1204.	5.3	41
36	Early Treatment with Quinidine in 2 Patients with Epilepsy of Infancy with Migrating Focal Seizures (EIMFS) Due to Gain-of-Function KCNT1 Mutations: Functional Studies, Clinical Responses, and Critical Issues for Personalized Therapy. Neurotherapeutics, 2018, 15, 1112-1126.	4.4	56

#	Article	IF	CITATIONS
37	Pharmacological Targeting of Neuronal Kv7.2/3 Channels: A Focus on Chemotypes and Receptor Sites. Current Medicinal Chemistry, 2018, 25, 2637-2660.	2.4	43
38	Neonatal nonepileptic myoclonus is a prominent clinical feature of <i><scp>KCNQ</scp>2</i> gainâ€ofâ€function variants R201C and R201H. Epilepsia, 2017, 58, 436-445.	5.1	80
39	Effects of natural and synthetic isothiocyanate-based H 2 S-releasers against chemotherapy-induced neuropathic pain: Role of Kv7 potassium channels. Neuropharmacology, 2017, 121, 49-59.	4.1	90
40	Infantile spasms and encephalopathy without preceding neonatal seizures caused by <i>KCNQ2</i> R198Q, a gainâ€ofâ€function variant. Epilepsia, 2017, 58, e10-e15.	5.1	81
41	Differential Regulation of PI(4,5)P2 Sensitivity of Kv7.2 and Kv7.3 Channels by Calmodulin. Frontiers in Molecular Neuroscience, 2017, 10, 117.	2.9	14
42	Early-onset epileptic encephalopathy caused by a reduced sensitivity of Kv7.2 potassium channels to phosphatidylinositol 4,5-bisphosphate. Scientific Reports, 2016, 6, 38167.	3.3	40
43	Rapid and safe response to lowâ€dose carbamazepine in neonatal epilepsy. Epilepsia, 2016, 57, 2019-2030.	5.1	92
44	<i>KCNQ2</i> encephalopathy. Neurology: Genetics, 2016, 2, e96.	1.9	196
45	β-Adrenergic response is counteracted by extremely-low-frequency pulsed electromagnetic fields in beating cardiomyocytes. Journal of Molecular and Cellular Cardiology, 2016, 98, 146-158.	1.9	9
46	Characterization of two de novo KCNT1 mutations in children with malignant migrating partial seizures in infancy. Molecular and Cellular Neurosciences, 2016, 72, 54-63.	2.2	77
47	Tryptamine-Based Derivatives as Transient Receptor Potential Melastatin Type 8 (TRPM8) Channel Modulators. Journal of Medicinal Chemistry, 2016, 59, 2179-2191.	6.4	40
48	Expression and function of Kv7.4 channels in rat cardiac mitochondria: possible targets for cardioprotection. Cardiovascular Research, 2016, 110, 40-50.	3.8	65
49	Molecular pathophysiology and pharmacology of the voltage-sensing module of neuronal ion channels. Frontiers in Cellular Neuroscience, 2015, 9, 259.	3.7	13
50	A novel <i>KCNQ3</i> mutation in familial epilepsy with focal seizures and intellectual disability. Epilepsia, 2015, 56, e15-20.	5.1	66
51	Epilepsy-causing mutations in Kv7.2 C-terminus affect binding and functional modulation by calmodulin. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2015, 1852, 1856-1866.	3.8	40
52	Early-Onset Epileptic Encephalopathy Caused by Gain-of-Function Mutations in the Voltage Sensor of K _v 7.2 and K _v 7.3 Potassium Channel Subunits. Journal of Neuroscience, 2015, 35, 3782-3793.	3.6	151
53	Protective Role of Kv7 Channels in Oxygen and Glucose Deprivation-Induced Damage in Rat Caudate Brain Slices. Journal of Cerebral Blood Flow and Metabolism, 2015, 35, 1593-1600.	4.3	11
54	PIP2 and Surface Expression Underlie Apo-Calmodulin Dependent Kv7.2/KCNQ2 Current Potentiation. Biophysical Journal, 2015, 108, 349a.	0.5	0

#	Article	IF	CITATIONS
55	Novel <i>KCNQ2</i> and <i>KCNQ3</i> Mutations in a Large Cohort of Families with Benign Neonatal Epilepsy: First Evidence for an Altered Channel Regulation by Syntaxin-1A. Human Mutation, 2014, 35, 356-367.	2.5	82
56	Calcium-Independent Potentation of Kv7.2 Current Density by Calmodulin. Biophysical Journal, 2014, 106, 141a-142a.	0.5	0
57	Functional and biochemical interaction between PPARα receptors and TRPV1 channels: Potential role in PPARα agonists-mediated analgesia. Pharmacological Research, 2014, 87, 113-122.	7.1	33
58	Large Conductance Calcium-Activated Potassium Channels: Their Expression and Modulation of Glutamate Release from Nerve Terminals Isolated from Rat Trigeminal Caudal Nucleus and Cerebral Cortex. Neurochemical Research, 2014, 39, 901-910.	3.3	19
59	Critical role of large-conductance calcium- and voltage-activated potassium channels in leptin-induced neuroprotection of N-methyl-d-aspartate-exposed cortical neurons. Pharmacological Research, 2014, 87, 80-86.	7.1	19
60	The endocannabinoid 2-AG controls skeletal muscle cell differentiation via CB1 receptor-dependent inhibition of K _v 7 channels. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E2472-81.	7.1	75
61	The Ever Changing Moods of Calmodulin: How Structural Plasticity Entails Transductional Adaptability. Journal of Molecular Biology, 2014, 426, 2717-2735.	4.2	87
62	Genetic testing in benign familial epilepsies of the first year of life: Clinical and diagnostic significance. Epilepsia, 2013, 54, 425-436.	5.1	110
63	Subtype-Selective Activation of K _v 7 Channels by AaTXK <i>β</i> _(2–64) , a Novel Toxin Variant from the <i>Androctonus australis</i> Scorpion Venom. Molecular Pharmacology, 2013, 84, 763-773.	2.3	14
64	Expression and motor functional roles of voltage-dependent type 7 K+ channels in the human taenia coli. European Journal of Pharmacology, 2013, 721, 12-20.	3.5	10
65	Isoxazole derivatives as potent transient receptor potential melastatin type 8 (TRPM8) agonists. European Journal of Medicinal Chemistry, 2013, 69, 659-669.	5.5	22
66	Vasorelaxation by hydrogen sulphide involves activation of Kv7 potassium channels. Pharmacological Research, 2013, 70, 27-34.	7.1	105
67	Activation and desensitization of <scp>TRPV1</scp> channels in sensory neurons by the PPARα agonist palmitoylethanolamide. British Journal of Pharmacology, 2013, 168, 1430-1444.	5.4	118
68	Addressing the use of PDIF-CN2 molecules in the development of n-type organic field-effect transistors for biosensing applications. Biochimica Et Biophysica Acta - General Subjects, 2013, 1830, 4365-4373.	2.4	22
69	New advances in beta-blocker therapy in heart failure. Frontiers in Physiology, 2013, 4, 323.	2.8	56
70	Genotype–phenotype correlations in neonatal epilepsies caused by mutations in the voltage sensor of K _v 7.2 potassium channel subunits. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 4386-4391.	7.1	154
71	Specification of skeletal muscle differentiation by repressor element-1 silencing transcription factor (REST)-regulated K _v 7.4 potassium channels. Molecular Biology of the Cell, 2013, 24, 274-284.	2.1	42
72	Molecular and pharmacological evidence for a facilitatory functional role of preâ€synaptic GLUK 2/3 kainate receptors on GABA release in rat trigeminal caudal nucleus. European Journal of Pain, 2012, 16, 1148-1157.	2.8	2

#	Article	IF	CITATIONS
73	Gating Currents from Kv7 Channels Carrying Neuronal Hyperexcitability Mutations in the Voltage-Sensing Domain. Biophysical Journal, 2012, 102, 1372-1382.	0.5	42
74	Cell viability studies and operation in cellular culture medium of n-type organic field-effect transistors. Journal of Applied Physics, 2012, 111, 034702.	2.5	9
75	Amyloid-β Protein Precursor Regulates Phosphorylation and Cellular Compartmentalization of Microtubule Associated Protein Tau. Journal of Alzheimer's Disease, 2012, 29, 211-227.	2.6	19
76	KV7 channels regulate muscle tone and nonadrenergic noncholinergic relaxation of the rat gastric fundus. Pharmacological Research, 2011, 64, 397-409.	7.1	31
77	Gating Currents from Neuronal KV7 Channels Carrying BFNS-Causing Mutations in the S4 Segment of the Voltage Sensing Domain. Biophysical Journal, 2011, 100, 426a.	0.5	Ο
78	Involvement of inward rectifier and M-type currents in carbachol-induced epileptiform synchronization. Neuropharmacology, 2011, 60, 653-661.	4.1	12
79	The Voltage-Sensing Domain of Kv7.2 Channels as a Molecular Target for Epilepsy-Causing Mutations and Anticonvulsants. Frontiers in Pharmacology, 2011, 2, 2.	3.5	24
80	Driving With No Brakes: Molecular Pathophysiology of Kv7 Potassium Channels. Physiology, 2011, 26, 365-376.	3.1	118
81	A new Italian FHM2 family: Clinical aspects and functional analysis of the disease-associated mutation. Cephalalgia, 2011, 31, 808-819.	3.9	27
82	Preâ€synaptic BK channels selectively control glutamate versus GABA release from cortical and hippocampal nerve terminals. Journal of Neurochemistry, 2010, 115, 411-422.	3.9	43
83	Neuronal potassium channel openers in the management of epilepsy: role and potential of retigabine. Clinical Pharmacology: Advances and Applications, 2010, 2, 225.	1.2	23
84	Expression, Localization, and Pharmacological Role of K _v 7 Potassium Channels in Skeletal Muscle Proliferation, Differentiation, and Survival after Myotoxic Insults. Journal of Pharmacology and Experimental Therapeutics, 2010, 332, 811-820.	2.5	65
85	AMPA- and P2X7-receptor-mediated facilitation of [3H]d-aspartate release from nerve terminals isolated from the rat caudal brainstem. Neurochemistry International, 2010, 57, 623-628.	3.8	10
86	Tertiapin. , 2010, , 1-6.		0
87	Mepivacaine. , 2010, , 1-9.		0
88	Sipatrigine. , 2010, , 1-9.		0
89	Dequalinium. , 2009, , 1-4.		0
90	Barium. , 2009, , 1-8.		0

#	Article	IF	CITATIONS
91	Coupling between the voltage-sensing and phosphatase domains of Ci-VSP. Journal of General Physiology, 2009, 134, 5-14.	1.9	63
92	Neutralization of a unique, negatively-charged residue in the voltage sensor of KV7.2 subunits in a sporadic case of benign familial neonatal seizures. Neurobiology of Disease, 2009, 34, 501-510.	4.4	25
93	Corrigendum to "Neutralization of a unique, negatively-charged residue in the voltage sensor of KV7.2 subunits in a sporadic case of benign familial neonatal seizures―[Neurobiol. Dis. 34 (2009) 501–510]. Neurobiology of Disease, 2009, 35, 318.	4.4	4
94	Activation of preâ€synaptic Mâ€type K ⁺ channels inhibits [³ H] <scp>d</scp> â€aspartate release by reducing Ca ²⁺ entry through P/Qâ€type voltageâ€gated Ca ²⁺ channels. Journal of Neurochemistry, 2009, 109, 168-181.	3.9	25
95	Calyculin. , 2009, , 1-4.		0
96	Gating currents from neuronal Kv7 channels. Biophysical Journal, 2009, 96, 656a.	0.5	0
97	Gating currents from neuronal K _V 7.4 Channels: General features and correlation with the ionic conductance. Channels, 2009, 3, 277-286.	2.8	28
98	Hexamethonium. , 2009, , 1-5.		0
99	Clofilium. , 2009, , 1-6.		0
100	1-Ethyl-Benzimidazolinone. , 2009, , 1-4.		0
101	Pi1-NH2. , 2009, , 1-3.		0
102	Paxilline. , 2009, , 1-5.		0
103	Ts kappa. , 2009, , 1-4.		0
104	Stromatopelma Toxin. , 2009, , 1-3.		0
105	Po5., 2009, , 1-3.		0
106	BMS-204352. , 2009, , 1-6.		0
107	Slotoxin. , 2009, , 1-3.		0
108	4-Aminopyridine. , 2009, , 1-7.		0

#	Article	IF	CITATIONS
109	Lei-Dab 7. , 2009, , 1-6.		0
110	Gating currents from neuronal K(V)7.4 channels: general features and correlation with the ionic conductance. Channels, 2009, 3, 274-83.	2.8	22
111	Low expression of Kv7/M channels facilitates intrinsic and network bursting in the developing rat hippocampus. Journal of Physiology, 2008, 586, 5437-5453.	2.9	61
112	Gating Consequences of Charge Neutralization of Arginine Residues in the S4 Segment of Kv7.2, an Epilepsy-Linked K+ Channel Subunit. Biophysical Journal, 2008, 95, 2254-2264.	0.5	36
113	Molecular pharmacology and therapeutic potential of neuronal Kv7-modulating drugs. Current Opinion in Pharmacology, 2008, 8, 65-74.	3.5	140
114	Cardiotoxic Effects of Antihistamines: From Basics to Clinics (…and Back). Chemical Research in Toxicology, 2008, 21, 997-1004.	3.3	20
115	HYPEREKPLEXIA CAUSED BY DOMINANT-NEGATIVE SUPPRESSION OF GLYRA1 FUNCTION. Neurology, 2007, 68, 1947-1949.	1.1	10
116	Correlating the Clinical and Genetic Features of Benign Familial Neonatal Seizures (BFNS) with the Functional Consequences of Underlying Mutations. Channels, 2007, 1, 228-233.	2.8	29
117	Up-Regulation and Increased Activity of KV3.4 Channels and Their Accessory Subunit MinK-Related Peptide 2 Induced by Amyloid Peptide Are Involved in Apoptotic Neuronal Death. Molecular Pharmacology, 2007, 72, 665-673.	2.3	75
118	Atypical Gating Of M-Type Potassium Channels Conferred by Mutations in Uncharged Residues in the S4 Region of KCNQ2 Causing Benign Familial Neonatal Convulsions. Journal of Neuroscience, 2007, 27, 4919-4928.	3.6	49
119	Involvement of KCNQ2 subunits in [3H]dopamine release triggered by depolarization and pre-synaptic muscarinic receptor activation from rat striatal synaptosomes. Journal of Neurochemistry, 2007, 102, 179-193.	3.9	51
120	Human neoplastic mesothelial cells express voltage-gated sodium channels involved in cell motility. International Journal of Biochemistry and Cell Biology, 2006, 38, 1146-1159.	2.8	51
121	Retigabine and flupirtine exert neuroprotective actions in organotypic hippocampal cultures. Neuropharmacology, 2006, 51, 283-294.	4.1	75
122	Mutational scanning of potassium, sodium and chloride ion channels in malignant migrating partial seizures in infancy. Brain and Development, 2006, 28, 76-79.	1.1	70
123	Decreased Subunit Stability as a Novel Mechanism for Potassium Current Impairment by a KCNQ2 C Terminus Mutation Causing Benign Familial Neonatal Convulsions. Journal of Biological Chemistry, 2006, 281, 418-428.	3.4	58
124	Nuclear factor-κB activation by reactive oxygen species mediates voltage-gated K+ current enhancement by neurotoxic β-amyloid peptides in nerve growth factor-differentiated PC-12 cells and hippocampal neurones. Journal of Neurochemistry, 2005, 94, 572-586.	3.9	41
125	A y+LAT-1 mutant protein interferes with y+LAT-2 activity: implications for the molecular pathogenesis of lysinuric protein intolerance. European Journal of Human Genetics, 2005, 13, 628-634.	2.8	21
126	Lysinuric protein intolerance: identification and functional analysis of mutations of the SLC7A7 gene. Human Mutation, 2005, 25, 410-410.	2.5	19

#	Article	IF	CITATIONS
127	Functional analysis of novel KCNQ2 and KCNQ3 gene variants found in a large pedigree with benign familial neonatal convulsions (BFNC). Neurogenetics, 2005, 6, 185-193.	1.4	26
128	M Channels Containing KCNQ2 Subunits Modulate Norepinephrine, Aspartate, and GABA Release from Hippocampal Nerve Terminals. Journal of Neuroscience, 2004, 24, 592-597.	3.6	158
129	A Novel Hyperekplexia-causing Mutation in the Pre-transmembrane Segment 1 of the Human Glycine Receptor I±1 Subunit Reduces Membrane Expression and Impairs Gating by Agonists. Journal of Biological Chemistry, 2004, 279, 25598-25604.	3.4	49
130	First- and second-generation H1 antihistamines: from the molecular basis of their interaction with HERG K+ channels to physiological and pathophysiological implication. Clinical and Experimental Allergy Reviews, 2004, 4, 183-190.	0.3	2
131	Discussuion Session 7. Treatment and prevention of asthma and allergic disorders. Clinical and Experimental Allergy Reviews, 2004, 4, 191-193.	0.3	0
132	A novel mutation in KCNQ2 associated with BFNC, drug resistant epilepsy, and mental retardation. Neurology, 2004, 63, 57-65.	1.1	146
133	Differential expression of the Na+-Ca2+ exchanger transcripts and proteins in rat brain regions. Journal of Comparative Neurology, 2003, 461, 31-48.	1.6	106
134	Expression pattern of the ether-a-gogo-related (ERG) k+ channel-encoding genes ERG1, ERG2, and ERG3 in the adult rat central nervous system. Journal of Comparative Neurology, 2003, 466, 119-135.	1.6	95
135	Consensus group on newâ€generation antihistamines (CONGA): present status and recommendations. Clinical and Experimental Allergy, 2003, 33, 1305-1324.	2.9	161
136	A novel KCNQ2 K ⁺ channel mutation in benign neonatal convulsions and centrotemporal spikes. Neurology, 2003, 61, 131-134.	1.1	57
137	Heterologous Expression Systems and Screening Technologies in Ion Channel Drug Discovery. , 2003, , 227-244.		2
138	Histidines 578 and 587 in the S5-S6Linker of the Human Ether-a-gogo Related Gene-1K+ Channels Confer Sensitivity to Reactive Oxygen Species. Journal of Biological Chemistry, 2002, 277, 8912-8919.	3.4	13
139	Modulation of ion channels by reactive oxygen and nitrogen species: a pathophysiological role in brain aging?. Neurobiology of Aging, 2002, 23, 819-834.	3.1	111
140	Benign Familial Neonatal Convulsions Caused by Altered Gating of KCNQ2/KCNQ3 Potassium Channels. Journal of Neuroscience, 2002, 22, RC199-RC199.	3.6	120
141	H ₁ â€antihistamines: inverse agonism, antiâ€inflammatory actions and cardiac effects. Clinical and Experimental Allergy, 2002, 32, 489-498.	2.9	388
142	Brain Distribution of the Na ⁺ /Ca ²⁺ Exchangerâ€Encoding Genes NCX1, NCX2, and NCX3 and Their Related Proteins in the Central Nervous System. Annals of the New York Academy of Sciences, 2002, 976, 394-404.	3.8	76
143	DPC-423 Bristol-Myers Squibb. Current Opinion in Investigational Drugs, 2002, 3, 252-4.	2.3	1
144	New Insights into the Second Generation Antihistamines. Drugs, 2001, 61, 207-236.	10.9	85

9

#	Article	IF	CITATIONS
145	â€Janus face' of nitric oxide action on plasma membrane and intracellular ionic channels. Archives of Gerontology and Geriatrics, 2001, 33, 379-394. Inhibition of depolarization-induced [3H]noradrenaline release from SH-SY5Y human neuroblastoma	3.0	2
146	cells by some second-generation H1 receptor antagonists through blockade of store-operated Ca2+ channels (SOCs)11Abbreviations: hERG, human Ether-a-go-go Related Gene; SOC, Ca2+ currents activated by [Ca2+]i store depletion; NE, norepinephrine; [K+]e, e xtracellular K+ concentration; [Ca2+]i, intracellular Ca2+ concentration; HBS, HEPES-buffered saline; SERCA,	4.4	17
147	sarcoplasmic-endoplasmic reticulum calcium ATPase; an. Biochemical Pharmacology, 2001, 62, 1229-1238. Histamine Induces Exocytosis and IL-6 Production from Human Lung Macrophages Through Interaction with H1 Receptors. Journal of Immunology, 2001, 166, 4083-4091.	0.8	135
148	Evaluation of the cardiac safety of second-generation antihistamines. Allergy: European Journal of Allergy and Clinical Immunology, 2000, 55, 22-30.	5.7	9
149	Novel insights into the molecular mechanism of the cardiac actions of histamine H 1 receptor antagonists. Dermatologic Therapy, 2000, 13, 361-373.	1.7	0
150	Inhibition of HERG1 K+ channels by the novel second-generation antihistamine mizolastine. British Journal of Pharmacology, 2000, 131, 1081-1088.	5.4	32
151	Do Glia Have Heart? Expression and Functional Role for <i>Ether-A-Go-Go</i> Currents in Hippocampal Astrocytes. Journal of Neuroscience, 2000, 20, 3915-3925.	3.6	92
152	Pharmacological Blockade of ERG K ⁺ Channels and Ca ²⁺ Influx through Store-Operated Channels Exerts Opposite Effects on Intracellular Ca ²⁺ Oscillations in Pituitary GH ₃ Cells. Molecular Pharmacology, 2000, 58, 1115-1128.	2.3	32
153	Retention in the Endoplasmic Reticulum as a Mechanism of Dominant-negative Current Suppression in Human Long QT Syndrome. Journal of Molecular and Cellular Cardiology, 2000, 32, 2327-2337.	1.9	96
154	Cardiotoxic potential and CNS effects of first-generation antihistamines. Trends in Pharmacological Sciences, 2000, 21, 52-56.	8.7	72
155	Electrophysiological and Molecular Basis for the Adverse Cardiovascular Effects of Histamine H1 Receptor Antagonists. , 2000, , 673-688.		Ο
156	Modulation of the K+Channels Encoded by the Human Ether-a-Gogo-Related Gene-1 (hERG1) by Nitric Oxide. Molecular Pharmacology, 1999, 56, 1298-1308.	2.3	37
157	Cardiac ion channels and antihistamines: possible mechanisms of cardiotoxicity. Clinical and Experimental Allergy, 1999, 29, 182-189.	2.9	63
158	Effects of manidipine and nitrendipine enantiomers on the plateau phase of K+-induced intracellular Ca2+ increase in GH3 cells. European Journal of Pharmacology, 1999, 376, 169-178.	3.5	12
159	Studies on maitotoxin-induced intracellular Ca(2+) elevation in chinese hamster ovary cells stably transfected with cDNAs encoding for L-type Ca(2+) channel subunits. Journal of Pharmacology and Experimental Therapeutics, 1999, 290, 725-30.	2.5	11
160	The Gene Encoding a Cationic Amino Acid Transporter (SLC7A4) Maps to the Region Deleted in the Velocardiofacial Syndrome. Genomics, 1998, 49, 230-236.	2.9	52
161	Human Ether-a-gogo Related Gene (HERG) K Channels as Pharmacological Targets. Biochemical Pharmacology, 1998, 55, 1741-1746.	4.4	61
162	Molecular Basis for the Lack of HERG K+ Channel Block-Related Cardiotoxicity by the H1 Receptor Blocker Cetirizine Compared with Other Second-Generation Antihistamines. Molecular Pharmacology, 1998, 54, 113-121.	2.3	130

#	Article	IF	CITATIONS
163	Regulation of the human ether-a-gogo related gene (HERG) K ⁺ channels by reactive oxygen species. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 11698-11703.	7.1	80
164	Felbamate inhibits cloned voltage-dependent Na+ channels from human and rat brain. European Journal of Pharmacology, 1996, 316, 373-377.	3.5	32
165	Protein-tyrosine Kinases Activate while Protein-tyrosine Phosphatases Inhibit L-type Calcium Channel Activity in Pituitary GH3 Cells. Journal of Biological Chemistry, 1996, 271, 9441-9446.	3.4	82
166	Regulation by Spermine of Native Inward Rectifier K+ Channels in RBL-1 Cells. Journal of Biological Chemistry, 1996, 271, 6114-6121.	3.4	65
167	Structural motifs underlying voltage-dependent K+ channel function. Kidney International, 1995, 48, 918-922.	5.2	4
168	Characterization of a Human and Murine Gene (CLCN3) Sharing Similarities to Voltage-Gated Chloride Channels and to a Yeast Integral Membrane Protein. Genomics, 1995, 27, 131-141.	2.9	72
169	Pharmacological implications of inward rectifier K+ channels regulation by cytoplasmic polyamines. Pharmacological Research, 1995, 32, 335-344.	7.1	7
170	Cloning and Functional Expression of an Inwardly Rectifying K + Channel From Human Atrium. Circulation Research, 1995, 76, 343-350.	4.5	70
171	Cloned Human Inward Rectifier K + Channel as a Target for Class III Methanesulfonanilides. Circulation Research, 1995, 77, 1151-1155.	4.5	23
172	Spermine and spermidine as gating molecules for inward rectifier K+ channels. Science, 1994, 266, 1068-1072.	12.6	513
173	Specification of pore properties by the carboxyl terminus of inwardly rectifying K+ channels. Science, 1994, 264, 844-847.	12.6	160
174	Gating of inwardly rectifying K+ channels localized to a single negatively charged residue. Nature, 1994, 371, 246-249.	27.8	254
175	Rescue of lethal subunits into functional K+ channels. Biophysical Journal, 1994, 66, 179-190.	0.5	12
176	Structural Correlates of K+ Channel Function. Physiology, 1994, 9, 169-173.	3.1	4
177	Comparison of H5, S6, and H5-S6 exchanges on pore properties of voltage-dependent K+ channels. Journal of Biological Chemistry, 1994, 269, 13867-73.	3.4	40
178	Inactivation determined by a single site in K+ pores. Pflugers Archiv European Journal of Physiology, 1993, 422, 354-363.	2.8	90
179	Regulation of K+/Rb+ selectivity and internal TEA blockade by mutations at a single site in K+ pores. Pflugers Archiv European Journal of Physiology, 1993, 423-423, 104-112.	2.8	41
180	Gadolinium and neomycin block voltage-sensitive Ca2+ channels without interfering with the Na+î—,Ca2+ antiporter in brain nerve endings. European Journal of Pharmacology, 1993, 245, 97-103.	2.6	26

#	Article	IF	CITATIONS
181	The Potassium Pore and Its Regulation. Annals of the New York Academy of Sciences, 1993, 707, 74-80.	3.8	6
182	Gating currents of the cloned delayed-rectifier K+ channel DRK1 Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 4758-4762.	7.1	50
183	The Na+-Ca++ exchanger in central nerve endings: The relationship between its pharmacological blockade and dopamine release from tuberoinfundibular hypothalamic neurons. Neurochemistry International, 1992, 20, 95-99.	3.8	7
184	Differences between the deep pores of K+ channels determined by an interacting pair of nonpolar amino acids. Neuron, 1992, 8, 499-505.	8.1	106
185	Gating currents from a delayed rectifier K+ channel with altered pore structure and function. Biophysical Journal, 1992, 62, 34-36.	0.5	21
186	A single nonpolar residue in the deep pore of related K+ channels acts as a K+:Rb+ conductance switch. Biophysical Journal, 1992, 62, 136-144.	0.5	67
187	Novel voltage clamp to record small, fast currents from ion channels expressed in Xenopus oocytes. Biophysical Journal, 1992, 61, 78-82.	0.5	179
188	The Na+î—,Ca2+ exchanger activity in cerebrocortical nerve endings is reduced in old compared to young and mature rats when it operates as a Ca2+ influx or efflux pathway. Biochimica Et Biophysica Acta - Biomembranes, 1992, 1107, 175-178.	2.6	18
189	Maitotoxin, a novel activator of mediator release from human basophils, induces large increases in cytosolic calcium resulting in histamine, but not leukotriene C4, release. Journal of Pharmacology and Experimental Therapeutics, 1992, 263, 979-86.	2.5	7
190	Cytoplasmic alkalinization induced by insulin through an activation of Na+î—,H+ antiporter inhibits tyrosine hydroxylase activity in striatal synaptosomes. Biochemical Pharmacology, 1991, 41, 1279-1282.	4.4	11
191	Adenosine Receptors Modulate the Na+-Ca2+Exchanger in Cerebral Nerve Endings. Annals of the New York Academy of Sciences, 1991, 639, 166-168.	3.8	2
192	Voltage-dependent inhibition and facilitation of Ca channel activation by GTP-Î ³ -S and Ca-agonists in adult rat sensory neurons. Neuroscience Letters, 1991, 123, 203-207.	2.1	17
193	Exchange of conduction pathways between two related K+ channels. Science, 1991, 251, 942-944.	12.6	391
194	Ibopamine-induced reduction of serum prolactin level and milk secretion in puerperal women. European Journal of Clinical Pharmacology, 1990, 39, 133-135.	1.9	3
195	Effect of maitotoxin on cytosolic Ca2+ levels and membrane potential in purified rat brain synaptosomes. Biochimica Et Biophysica Acta - Biomembranes, 1990, 1026, 126-132.	2.6	25
196	Possible involvement of Ca++ ions, protein kinase C and Na+-H+ antiporter in insulin-induced endogenous dopamine release from tuberoinfundibular neurons. Life Sciences, 1990, 46, 885-894.	4.3	8
197	Na(+)-Ca2+ exchange activity in central nerve endings. II. Relationship between pharmacological blockade by amiloride analogues and dopamine release from tuberoinfundibular hypothalamic neurons. Molecular Pharmacology, 1990, 38, 393-400.	2.3	20
198	Pharmacological characterization of serotonin receptors involved in the control of prolactin secretion. European Journal of Pharmacology, 1989, 162, 371-373.	3.5	70

#	Article	IF	CITATIONS
199	Cobalt-sensitive and dihydropyridine-insensitive stimulation of dopamine release from tuberoinfundibular neurons by high extracellular concentrations of barium ions. Brain Research, 1989, 488, 114-120.	2.2	6
200	Characteristics of barium-induced dopamine release from tuberoinfundibular hypothalamic neurons. Pharmacological Research Communications, 1988, 20, 223-224.	0.2	0
201	The inhibition of the Na+-Ca++ rather than of the Na+-H+ exchange system modulates dopamine release from tuberoinfundibular neurons. Pharmacological Research Communications, 1988, 20, 8.	0.2	0
202	Pharmacological characterization of serotonin receptors involved in the control of prolactin secretion. Pharmacological Research Communications, 1988, 20, 26.	0.2	1
203	Characterization of the membrane Ca++-transporting systems in striatal synaptosomes. Pharmacological Research Communications, 1988, 20, 377.	0.2	0
204	Involvement of the Na+-H+ antiporter on the effect of protein kinase-C activation on dopamine synthesis in rat corpus striatum. Pharmacological Research Communications, 1988, 20, 1099-1100.	0.2	0
205	Effect of different Ca2+ entry blockers on dopamine-induced inhibition of in vitro prolactin secretion. European Journal of Pharmacology, 1988, 146, 201-206.	3.5	12
206	Evidence for a differential interaction of buprenorphine with opiate receptor subtypes controlling prolactin secretion. European Journal of Pharmacology, 1988, 145, 257-260.	3.5	5
207	Pure uptake blockers of dopamine can reduce prolactin secretion: Studies with diclofensine. Life Sciences, 1988, 42, 2161-2169.	4.3	5
208	Plasma Prolactin Levels in the Inferior Petrosal Sinuses in Various Pituitary Disorders during Perihypophyseal Phlebography. Neuroendocrinology, 1987, 46, 333-338.	2.5	14
209	Possible inhibitory role of histamine H2 receptors in the control of basal TSH secretion in male rats: Studies with dimaprit, a selective H2 receptor agonist. Journal of Neural Transmission, 1987, 69, 313-318.	2.8	3
210	Domperidone antagonizes bromoergocriptine — Induced nausea and vomiting without affecting its inhibition of prolactin secretion in puerperal women. European Journal of Clinical Pharmacology, 1987, 32, 457-460.	1.9	6
211	Effect of different organic and inorganic blockers of calcium entry on the release of endogenous dopamine from tuberoinfundibular neurones. Neuropharmacology, 1986, 25, 527-532.	4.1	11
212	Maitotoxin and BAY-K-8644: two putative calcium channel activators with different effects on endogenous dopamine release from tuberoinfundibular neurons. Brain Research, 1986, 381, 356-358.	2.2	22
213	Endogenous dopamine release from tuberoinfundibular neurons: Does calmodulin play any role?. Naunyn-Schmiedeberg's Archives of Pharmacology, 1986, 333, 224-228.	3.0	0
214	Reduced tuberoinfundibular dopaminergic neuronal function in rats after long-term withdrawal of estrogen treatment. Experientia, 1986, 42, 425-427.	1.2	1
215	Dual effect of verapamil on K+-evoked release of endogenous dopamine from arcuate nucleus-median eminence complex. Neuroscience Letters, 1984, 50, 269-272.	2.1	9
216	Functional Characterization of Two Variants at the Intron 6—Exon 7 Boundary of the KCNQ2 Potassium Channel Gene Causing Distinct Epileptic Phenotypes. Frontiers in Pharmacology, 0, 13, .	3.5	0